Pralmorelin (GHRP-2)
Also known as: KP-102, GPA 748
Pralmorelin (GHRP-2), also called KP-102 or GPA 748, is a diagnostic GH secretagogue in the Growth Hormone Secretagogue class. Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone.
For research use only.
Key Facts
- CAS
- 158861-67-7
- Molecular Weight (MW)
- 801.98 g/mol
- Half-life
- Reported short; human diagnostic use in Japan
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- Yes
- Administration Route
- Intravenous
- Frequency
- Single bolus as a stimulation test
- Last updated
- Sep 6, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GHSR
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 11
- Listed offers
- 16
- Median price per mg
- $5.70/mg
- Typical $3.99–$8.50/mg
Research summary
Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin).
Peptide Library's Pralmorelin (GHRP-2) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Pralmorelin (GHRP-2) dosage chart
GHRP-2, developed as pralmorelin, has established human dosing for one narrow purpose: a 100 mcg intravenous bolus used as a growth hormone stimulation test. It is a recognised diagnostic alternative to the insulin tolerance test in Japan. There is no FDA-labelled product and no trial establishing a repeated-dosing regimen for growth hormone or body-composition use.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 100 mcg intravenous bolus (diagnostic test dose) |
| Route | Intravenous |
| Frequency | Single bolus as a stimulation test |
| Duration studied | Acute; sampling over 60 minutes |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Vasopressin secretion study in healthy men (2010)Clinical trial · Human endocrine physiology study | 10 healthy men, fasting and non-fasting | 100 mcg | Intravenous bolus | Single dose | Sampling at 15, 30, 45 and 60 minutes | ACTH, GH, FSH, LH, prolactin, TSH and vasopressin responses | GH-releasing peptide-2 does not stimulate arginine vasopressin secretion in healthy men. Endocr J. 2010. |
| Diagnostic comparison against the insulin tolerance test (2013)Clinical trial · Diagnostic accuracy study | 71 pre-operative adults with pituitary tumours, aged 18-65 | Per the standard GHRP-2 test protocol | Intravenous | Single stimulation test | Acute | Diagnosis of adult growth hormone deficiency versus the insulin tolerance test | The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients. Endocr J. 2013. |
| Development profile - pralmorelinResearch-reported · Drug development profile | Development-stage summary | No maintenance regimen reported | Various | — | — | Development status of GHRP-2 / KP-102 | Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN. Drugs R D. 2004. |
Where sources disagree
- The 100 mcg dose is a single diagnostic stimulus given once in a clinic to provoke a measurable growth hormone response. It is not a treatment dose, and nothing about it validates repeated administration. GHRP-2 is nonetheless sold with protocols of 100-300 mcg two or three times daily.
- GHRP-2 raises ACTH, cortisol and prolactin as well as growth hormone. That is documented in the same human studies used to support its growth hormone effect.
- Approval as a diagnostic agent in Japan does not create a US approved dose, and DailyMed lists no product under pralmorelin or GHRP-2.
Reconstitution
Common research vial sizes: 5 mg, 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Injection Sites
- Per protocol
- Timing Notes
- Ghrelin receptor (GHSR) agonist
Sequence & molecular data
| Molecular formula | C45H55N9O6 |
|---|---|
| Molecular weight | 801.98 g/mol |
| CAS number | 158861-67-7 |
| Half-life | Reported short; human diagnostic use in Japan |
| Appearance | White lyophilized powder (acetate) |
| Formulation | Lyophilized Powder |
| PubChem CID | 6918245 |
| FDA UNII | E6S6E1F19M |
| ChEMBL | CHEMBL106593 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone. It is more potent than GHRP-6 at releasing growth hormone but retains meaningful activity on the corticotroph axis, commonly raising ACTH and cortisol, and it stimulates appetite. It has an approved diagnostic use in Japan as an intravenous test of growth hormone secretory reserve; that single-dose diagnostic context is pharmacologically distinct from the repeated subcutaneous research use for which it is sold elsewhere.
Origin
Synthetic hexapeptide GHRP.
Targets
Studies
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN
- Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
- Detection of GHRP-2 and GHRP-6 in urine samples from athletes
- Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy
Regulatory & research status
Pralmorelin (GHRP-2) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
Benefits
Pralmorelin (GHRP-2) side effects
Pralmorelin (GHRP-2) has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Hunger
- Cortisol rise
- Flushing
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Pralmorelin (GHRP-2): frequently asked questions
What is Pralmorelin (GHRP-2)?
Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin).
How does Pralmorelin (GHRP-2) work?
Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone. It is more potent than GHRP-6 at releasing growth hormone but retains meaningful activity on the corticotroph axis, commonly raising ACTH and cortisol, and it stimulates appetite.
Is Pralmorelin (GHRP-2) FDA approved?
No. Pralmorelin (GHRP-2) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Pralmorelin (GHRP-2)?
Reported half-life for Pralmorelin (GHRP-2) is Reported short; human diagnostic use in Japan. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Pralmorelin (GHRP-2) banned in sport?
Pralmorelin (GHRP-2) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Pralmorelin (GHRP-2)?
Compounds most often compared with Pralmorelin (GHRP-2) include Ipamorelin, GHRP-6, GHRP-1 and Hexarelin (Examorelin). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN — Drugs R D, 2004External reference
- Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial — Drug Test Anal, 2019External reference
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026External reference
- Detection of GHRP-2 and GHRP-6 in urine samples from athletes — Drug Test Anal, 2015External reference
- Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy — J Pain Palliat Care Pharmacother, 2022External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 6, 2026 · Version 2
This Pralmorelin (GHRP-2) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Pralmorelin (GHRP-2) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →